Schmid, P., & Schneeweiss, A. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Oncology, 21(1), . https://doi.org/10.1016/S1470-2045(19)30689-8
Chicago-Zitierstil (17. Ausg.)Schmid, Peter, und Andreas Schneeweiss. "Atezolizumab Plus Nab-paclitaxel as First-line Treatment for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 21, no. 1 (2020). https://doi.org/10.1016/S1470-2045(19)30689-8.
MLA-Zitierstil (9. Ausg.)Schmid, Peter, und Andreas Schneeweiss. "Atezolizumab Plus Nab-paclitaxel as First-line Treatment for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 21, no. 1, 2020, https://doi.org/10.1016/S1470-2045(19)30689-8.